Based on the results of these trials, both nivolumab and pembrolizumab are approved in Japan for the treatment of unresectable, advanced or recurrent ESCC that has progressed following chemotherapy [19], although pembrolizumab use is restricted to patients with PD-L1-positive tumors [17, 20]. This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.